Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course Miltefosine and Antimony for Cutaneous Leishmaniasis
NCT01380301Phase 2Terminated
- Sponsor
- FOUNDATION FADER
- Start
- Mar 2007
- Primary completion
- Aug 2008
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of miltefosine and meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by FOUNDATION FADER. Primary endpoint: Healing of ulcers at 45 days. Started Mar 2007; status: terminated.
02
Drugs
miltefosinemeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01380301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380301.